Science 37

Expanding access to clinical trials—directly to patients 🧪📲

Science37 is redefining patient recruitment with a Direct-to-Patient (DTP) model that connects individuals to clinical studies—wherever they are.

By removing geographic barriers and simplifying participation, DTP helps sponsors and partners accelerate enrollment, improve diversity, and enhance the overall study experience.

👉 Learn more about the Direct-to-Patient approach: https://www.science37.com/direct-to-patient-site/

Smarter recruitment. Better access. Stronger outcomes.

Stay informed. Stay empowered. 🧠💙

At Science37, we’re committed to supporting healthcare professionals, researchers, and industry partners with relevant perspectives on conditions observed across our decentralized clinical studies.

Our blog content is designed to inform decision-making, highlight emerging trends, and provide valuable context across therapeutic areas—helping you better understand today’s evolving research landscape.

👉 Explore the latest insights: https://studies.science37.com/blogs/

Blogs - Science 37 Studies

What does it actually take to run a single clinical trial site across all 50 states?

Our CMO, Dr. Debra Weinstein, was recently interviewed by Clinical Trials Arena—which named Science 37 the 2025 Site Innovation Award winner—to share how Science 37’s Direct-to-Patient Site operates in practice.

Key topics covered in the interview include:

✅ 𝗦𝗼𝗹𝘃𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝗰𝗰𝗲𝘀𝘀 𝗚𝗮𝗽: How the core R&D problem has shifted from geographic access to scaling nationwide while maintaining regulatory rigor.

✅ 𝗧𝗵𝗲 𝗕𝗹𝘂𝗲𝗽𝗿𝗶𝗻𝘁 𝗳𝗼𝗿 𝗮 𝗡𝗮𝘁𝗶𝗼𝗻𝘄𝗶𝗱𝗲 𝗦𝗶𝘁𝗲: The pivotal decisions, like a 50-state investigator network, that allow a single "site" to operate across the entire U.S.

✅ 𝗔 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗲𝗱 𝗪𝗼𝗿𝗸𝗳𝗼𝗿𝗰𝗲: Why mobile research-grade nurses are critical for high-quality, consistent participant experiences.

✅ 𝗘𝗺𝗯𝗲𝗱𝗱𝗲𝗱 𝗜𝗻𝘀𝗽𝗲𝗰𝘁𝗶𝗼𝗻 𝗥𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: An operational model where quality assurance and data integrity are part of daily workflows.

✅ 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗘𝗻𝗿𝗼𝗹𝗹𝗺𝗲𝗻𝘁 𝗩𝗲𝗹𝗼𝗰𝗶𝘁𝘆: How centralized medical record acquisition reduces enrollment timelines from weeks to days.

✅ 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗢𝘃𝗲𝗿 𝗥𝗲𝗽𝗹𝗮𝗰𝗲𝗺𝗲𝗻𝘁: How a direct-to-patient model serves as an extension of traditional sites to prevent dropouts and supercharge retention.

Full interview here: https://www.clinicaltrialsarena.com/excellence-awards/clinical-trials-arena-excellence-awards-science-37/

Rare disease research is being transformed by decentralized trials, making it easier for patients to participate and helping researchers gather more meaningful data. By bringing studies closer to patients, these innovations are opening new doors for progress and access.

🔬💜 Learn how decentralized trials are impacting rare disease research and what this means for the future of care.
👉 Read the full article: https://www.science37.com/blog/rare-disease-research-the-impact-of-decentralized-trials/

Rare Disease Research: The Impact of Decentralized Trials | Science 37 Authors: Jonathan Cotliar, MD and Suzanne Pendl, MD Collectively, rare diseases are not so rare. […]

𝗧𝗵𝗲 𝗺𝗼𝗱𝗲𝗿𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝘀𝗶𝘁𝗲 𝗶𝘀 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝗰𝗼𝗻𝗳𝗶𝗻𝗲𝗱 𝘁𝗼 𝗮 𝗽𝗵𝘆𝘀𝗶𝗰𝗮𝗹 𝗹𝗼𝗰𝗮𝘁𝗶𝗼𝗻.

We’ve seen incredible advances in science, like precision medicine, gene therapies, and digital tools. But the way we deliver these trials to patients hasn’t changed in 30 years.

𝗧𝗵𝗲 𝗥𝗲𝗮𝗹𝗶𝘁𝘆: We design trials around site locations.
𝗧𝗵𝗲 𝗖𝗼𝗻𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲: 92% of eligible patients never have access.

The modern clinical trial site isn’t a building; it’s a capability. It’s the ability to bring research directly to patients' homes and the communities they live in, removing geographic barriers to participation.

🎤 Join Kelly McKee at the OECT Summit for a session on 𝘛𝘩𝘦 𝘌𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦 𝘔𝘰𝘥𝘦𝘳𝘯 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘛𝘳𝘪𝘢𝘭 𝘚𝘪𝘵𝘦. We can't wait!

𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗗𝗲𝘁𝗮𝗶𝗹𝘀:
📅 Thursday, April 16 | 9:50 am ET
📍 DoubleTree by Hilton Philadelphia Airport

For any parent, a child’s illness is a source of profound anxiety. When that illness is rare or chronic and treatment options include clinical research, the complexity of daily life multiples exponentially.

https://vimeo.com/1172167081?fl=pl&fe=cm

When Lucas’s parents learned about a clinical study for Fragile X Syndrome, they faced a common dilemma. With another son in school and a 5-hour trek to the nearest participating site, traditional site visits weren't just "difficult"—they were impossible.

By participating in the study with Science 37, the trial was brought into Lucas's "comfort zone." 🏠✨

𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲𝗶𝗿 𝗷𝗼𝘂𝗿𝗻𝗲𝘆:

• 𝗭𝗲𝗿𝗼 𝘁𝗿𝗮𝘃𝗲𝗹 𝗯𝘂𝗿𝗱𝗲𝗻: No 10-hour round trips to Memphis or Atlanta.

• 𝗧𝗵𝗲 𝗰𝗼𝗺𝗳𝗼𝗿𝘁 𝘇𝗼𝗻𝗲 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲: Procedures like blood draws—which can be overwhelming for children with Fragile X—became manageable because they happened at home.

• 𝗙𝗹𝗲𝘅𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝘁𝗵𝗮𝘁 𝗳𝗶𝘁𝘀: The team worked around the family’s school schedules and daily routines.

As Lucas's parents share in the video below, the results have been life-changing. We are proud to make research more accessible for families who need it most.

Supporting families like Lucas's is at the very heart of why we established our dedicated Pediatrics Department. Our team is focused on bridging the gap between research and the realities of daily life, ensuring that geography and logistics never stand in the way of hope.

Participant Family Testimonial - Fragile X Syndrome This is "Participant Family Testimonial - Fragile X Syndrome" by Science 37 on Vimeo, the home for high quality videos and the people who love them.

A couple of weeks ago, we shared the launch of Science 37's Pediatrics Department—a milestone designed to move research forward by meeting families exactly where they are.

Traditional trials often ask parents and children to revolve their lives around a clinic. We believe it should be the other way around.

By bringing specialized care into the home, we’re making it possible for children to participate in research without disrupting existing routines or schedules.

🧸 Read the announcement here: https://www.science37.com/science-37-launches-dedicated-pediatrics-department-to-expand-access-to-specialized-clinical-research-for-children-and-families/

Debra Weinstein

alResearch

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗵𝗮𝘃𝗲 𝗮 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝗽𝗿𝗼𝗯𝗹𝗲𝗺. For many patients, participating in research means driving hours to a site—or not participating at all. This creates "research deserts" and kills patient retention.

In this 20-minute episode, Tyler Van Horn, CEO at Science 37, explains how we've flipped the script with our Direct-to-Patient Site. Imagine a single site that covers all 50 states by bringing the trial to the patient’s living room.

𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗲𝗽𝗶𝘀𝗼𝗱𝗲 𝗰𝗼𝘃𝗲𝗿𝘀:
• Overview of Science 37's Direct-to-Patient Site
• Navigating sponsor adoption and common hurdles
• The reality of site conduct and operations in the home
• Ensuring investigator oversight and quality control
• Improving the caregiver and patient journey

If you’re curious about how direct-to-patient trials actually work in practice, this is a must-listen.

🎧 Click here to play the episode:

Breaking Down Geographic Barriers in Clinical Research - SCRS Talks What if patients could participate in clinical trials from their living room instead of driving hours to a site? Tyler Van Horn, CEO of Science 37, explains how their direct-to-patient site model works. With one site covering all 50 states, Scienc...

🎥 See the Future of Clinical Trials in Action

Discover how Science 37 is transforming research with its Direct-to-Patient model—bringing studies to participants, increasing access, and accelerating results.

👉 Watch the video now to learn more:
https://vimeo.com/1164343917?fl=pl&fe=cm

Experience how innovation is reshaping clinical trials from the ground up.

SCOPE 2026 - Site Innovation Award This is "SCOPE 2026 - Site Innovation Award" by Science 37 on Vimeo, the home for high quality videos and the people who love them.

GLP-1 agonists are reshaping the future of metabolic and heart health, offering new possibilities for managing conditions like diabetes and obesity while supporting overall wellness.

💊💙 Learn how GLP-1 agonists are transforming treatment and what it means for the future of care.
👉 Read the full article: https://studies.science37.com/glp-1-agonists-the-future-of-metabolic-and-heart-health/

GLP-1 Agonists: The Future of Metabolic and Heart Health - Science 37 Studies Discover how GLP-1 agonists are evolving beyond weight loss to become powerful regulators for heart and liver health. Learn about the science of metabolic health and how at-home clinical trials are shaping the future of chronic disease treatment.

Today, we are spotlighting some of our Research-Grade Nurses who power Science 37’s Pediatrics Department. 🧸

What does in-home "Research-Grade" nursing actually look like in Pediatrics?

It looks like a research-trained, GCP, HSR, and IATA certified nurse with experience in pediatric clinical settings and home-based care who understands exactly how to collect complex PK samples while keeping a five-year-old calm and engaged in their own home.

Being an at-home Clinical Research Nurse is more than just a title—it’s a badge of expertise that allows Science 37 to provide a seamless, safe, and rigorous trial experience for our youngest participants.

We believe that pediatric breakthroughs shouldn't be slowed down by geography. Thanks to our certified nursing network, we’re bringing the future of medicine to families across the U.S.
To learn more about how Science 37 supports pediatric research, visit our department page: https://www.science37.com/pediatric-clinical-research/